- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Afami-cel Elicits Durable Response Rates in Patients With Synovial Sarcoma or MRCLS
June 4th 2021, 11:25pm
Encouraging initial durability has been observed with afamitresgene autoleucel in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma, according to data from the phase 2 SPEARHEAD-1 trial.
Patritumab Deruxtecan Displays Durable Efficacy in EGFR TKI–Resistant EGFR+ NSCLC
June 4th 2021, 11:20pm
Patritumab deruxtecan was found to induce clinically meaningful, durable efficacy in heavily pretreated patients with EGFR-mutated non–small cell lung cancer who were resistant to EGFR TKIs.
Catequentinib Shows Promise in Treatment of Advanced Synovial Sarcoma
June 4th 2021, 10:57pm
Catequentinib improved disease control and progression-free survival in patients with advanced synovial sarcoma compared with dacarbazine.
Dr. Skoulidis on the Results of Subgroup Analyses of the CodeBreaK 100 Trial in KRAS G12C-Mutant NSCLC
June 4th 2021, 10:52pm
Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the results of subgroup analysis from the phase 2 CodeBreaK 100 trial in patients with KRAS G12C-mutant non–small cell lung cancer.
Ponatinib/Blinatumomab Combo Represents Promising Chemo-Free, HSCT-Sparing Treatment for Ph+ ALL
June 4th 2021, 10:50pm
The efficacy demonstrated with combination of ponatinib and blinatumomab represent a potentially promising chemotherapy-free, hematopoietic stem cell transplant–sparing treatment for patients with Philadelphia chromosome–positive acute lymphocytic leukemia.
Dr. Reck on Updated Results of the CheckMate 9LA Trial in Advanced NSCLC
June 4th 2021, 10:14pm
Martin Reck, MD, PhD, discusses updated results of the phase 3 CheckMate 9LA study in advanced non–small cell lung cancer.
TNO155 Demonstrates Manageable Safety and Consistent SHP2 Inhibition in Advanced Solid Tumors
June 4th 2021, 9:46pm
The investigational SHP2 inhibitor TNO155 demonstrated encouraging safety and tolerability, and consistent evidence of SHP2 inhibition in patients with advanced solid tumors.
Tucatinib Concentrations in CSF Demonstrated in HER2+ Metastatic Breast Cancer
June 4th 2021, 9:41pm
Evidence of tucatinib and its predominant metabolite, ONT-993, were detectable in the cerebrospinal fluid of patients with leptomeningeal metastasis HER2+ positive breast cancer marking a first for tucatinib distribution into the CSF seen in this patient population.
Dr. Choueiri on the Efficacy of Post-Nephrectomy, Adjuvant Pembrolizumab in RCC
June 4th 2021, 9:30pm
Toni K. Choueiri, MD, discusses the efficacy of pembrolizumab as a post-nephrectomy adjuvant therapy for patients with renal cell carcinoma from the phase 3 KEYNOTE-564 trial.
Nivolumab/Ipilimumab Plus Chemotherapy Shows Durable Benefit in Advanced NSCLC
June 4th 2021, 8:40pm
Nivolumab and ipilimumab plus 2 cycles of platinum-based chemotherapy demonstrated durable survival benefit vs chemotherapy alone in patients with advanced non–small cell lung cancer.
CLN-081 Elicits Encouraging Efficacy and Safety in EGFR Exon 20–Positive NSCLC
June 4th 2021, 7:50pm
CLN-081 demonstrated promising preliminary antitumor activity and an acceptable safety profile across all doses tested in patients with previously treated non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.
Tivozanib Doubles DOR Vs Sorafenib in mRCC
June 4th 2021, 7:43pm
Tivozanib led to a more than doubled median duration of response compared with sorafenib in patients with metastatic renal cell carcinoma.
Frontline Avelumab Maintenance Improves OS Regardless of Primary Tumor Site, Advanced Disease Type in Advanced Urothelial Cancer
June 4th 2021, 7:35pm
Avelumab as frontline maintenance plus best supportive care demonstrated a survival benefit compared with BSC alone across several previously unreported subgroups of patients with advanced urothelial cancer who have progressed on first-line platinum-containing chemotherapy.
Updated Findings Confirm Long-Term Survival Benefit with Durvalumab in NSCLC
June 4th 2021, 7:35pm
Data from an updated analysis of the phase 3 PACIFIC trial indicate that treatment with durvalumab after chemoradiotherapy is associated with long-term survival improvements in patients with unresectable stage III non-small cell lung cancer.
4-Year Findings Confirm Long-Term Benefit for Nivo/Ipi in First Line for mNSCLC
June 4th 2021, 6:15pm
The combination of nivolumab and ipilimumab continued to provide a durable, long-term overall survival benefit compared with chemotherapy after 4 years for patients with advanced non‒small cell lung cancer regardless of PD-L1 expression or histology.
Cirmtuzumab Plus Ibrutinib Had Overall Response Rates in MCL and CLL
June 4th 2021, 6:11pm
Cirmtuzumab and ibrutinib led to reported high overall response rates in patients with mantle cell lymphoma or chronic lymphocytic leukemia.
Antitumor Activity Demonstrated With Novel PSMA-Targeted Agent HPN424 in mCRPC
June 4th 2021, 6:04pm
The tri-specific half-life extended prostate-specific membrane antigen-targeting T cell engager HPN424 demonstrated antitumor activity and was well tolerated in patients with metastatic castration-resistant prostate cancer.
Mobocertinib Elicits Anticancer Activity in Platinum-Pretreated EGFR Exon 20 Insertion+ Advanced NSCLC
June 4th 2021, 5:50pm
Mobocertinib, a first-in-class, oral, EGFR TKI, induced rapid, deep, and durable responses and a manageable safety profile in patients with platinum-pretreated EGFR exon 20 insertion–positive metastatic non–small cell lung cancer.
Deep Responses Yielded by Cilta-Cel in Relapsed/Refractory Multiple Myeloma
June 4th 2021, 5:29pm
Deep and early responses were yielded with a single infusion of ciltacabtagene autoleucel in patients with previously treated, relapsed/refractory multiple myeloma.
Concurrent Pembrolizumab Plus Chemoradiation Therapy Elicits Antitumor Activity in NSCLC
June 4th 2021, 5:23pm
Pembrolizumab plus concurrent chemoradiation therapy induced antitumor effects in patients with unresectable, locally advanced, stage III non–small cell lung cancer irrespective of PD-L1 expression or tumor histology.